Blood Collection Device Minimizes Cellular DNA Release
|
By LabMedica International staff writers Posted on 27 Aug 2013 |
|
Image: Cell-free DNA BCT tube (Photo courtesy of Streck, Inc.).
Cell-free DNA (cfDNA) circulating in blood is currently used for noninvasive diagnostic and prognostic tests and minimizing background DNA is vital for detection of low abundance cfDNA.
A newly introduced blood collection device could reduce background levels of genomic DNA (gDNA) in plasma compared to standard tubes, when subjected to conditions that may occur during sample storage and shipping.
Scientists working for a commercial manufacturer took blood samples from healthy donors into tri-potassium ethylenediaminetetraacetic acid (K3EDTA) tubes and Cell-Free DNA BCT (BCT), which is a new collection device that contains a novel chemical cocktail. Samples were shaken or left unshaken to simulate shipping. In a shipping study, samples were shipped or not shipped. To assess temperature variations, samples were incubated at 6 °C, 22 °C, and 37 °C. In all cases, plasma was harvested by centrifugation and total plasma DNA (pDNA) assayed by quantitative real-time polymerase chain reaction (qPCR). The QIAamp Circulating Nucleic Acid Kit (Qiagen; Santa Clarita, CA, USA) was used for the extraction of pDNA.
The BCT tubes are manufactured by Streck, Inc., (Omaha, NE, USA) while the K3EDTA tubes were the BD Vacutainer, (Becton Dickinson; Franklin Lakes, NJ, USA). Shaking of blood drawn into K3EDTA tubes showed a significant increase in pDNA over 24 hours whereas no change was seen in Cell-Free DNA BCT tubes. Blood incubated at 6 °C, 22 °C, and 37 °C showed significant increases in pDNA isolated from K3EDTA tubes, while pDNA levels from Cell-Free DNA BCT remained stable over 14 days.
The novel stabilizing chemical cocktail prevents the release of gDNA into plasma post phlebotomy up to 14 days, avoiding labor-intensive requirements. Using this blood collection device, ex vivo storage at room temperature becomes possible, allowing flexibility for offsite blood drawn to be sent to centralized laboratories for downstream analysis of the cfDNA without preliminary centrifugations or cryopreservation.
The authors concluded that Cell-Free DNA BCT tubes prevent increases in background gDNA levels caused by temperature fluctuations or agitation that can occur during blood sample storage, shipping and processing. This novel blood-collection tube provides a method for obtaining high quality stabilized samples for rare DNA target detection and determining accurate cfDNA concentrations. The study was published on July 12, 2013, in the Journal of Clinical Laboratory Analysis.
Related Links:
Qiagen
Streck, Inc.
Becton Dickinson
 Reagent.jpg)
A newly introduced blood collection device could reduce background levels of genomic DNA (gDNA) in plasma compared to standard tubes, when subjected to conditions that may occur during sample storage and shipping.
Scientists working for a commercial manufacturer took blood samples from healthy donors into tri-potassium ethylenediaminetetraacetic acid (K3EDTA) tubes and Cell-Free DNA BCT (BCT), which is a new collection device that contains a novel chemical cocktail. Samples were shaken or left unshaken to simulate shipping. In a shipping study, samples were shipped or not shipped. To assess temperature variations, samples were incubated at 6 °C, 22 °C, and 37 °C. In all cases, plasma was harvested by centrifugation and total plasma DNA (pDNA) assayed by quantitative real-time polymerase chain reaction (qPCR). The QIAamp Circulating Nucleic Acid Kit (Qiagen; Santa Clarita, CA, USA) was used for the extraction of pDNA.
The BCT tubes are manufactured by Streck, Inc., (Omaha, NE, USA) while the K3EDTA tubes were the BD Vacutainer, (Becton Dickinson; Franklin Lakes, NJ, USA). Shaking of blood drawn into K3EDTA tubes showed a significant increase in pDNA over 24 hours whereas no change was seen in Cell-Free DNA BCT tubes. Blood incubated at 6 °C, 22 °C, and 37 °C showed significant increases in pDNA isolated from K3EDTA tubes, while pDNA levels from Cell-Free DNA BCT remained stable over 14 days.
The novel stabilizing chemical cocktail prevents the release of gDNA into plasma post phlebotomy up to 14 days, avoiding labor-intensive requirements. Using this blood collection device, ex vivo storage at room temperature becomes possible, allowing flexibility for offsite blood drawn to be sent to centralized laboratories for downstream analysis of the cfDNA without preliminary centrifugations or cryopreservation.
The authors concluded that Cell-Free DNA BCT tubes prevent increases in background gDNA levels caused by temperature fluctuations or agitation that can occur during blood sample storage, shipping and processing. This novel blood-collection tube provides a method for obtaining high quality stabilized samples for rare DNA target detection and determining accurate cfDNA concentrations. The study was published on July 12, 2013, in the Journal of Clinical Laboratory Analysis.
Related Links:
Qiagen
Streck, Inc.
Becton Dickinson
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent
Latest Technology News
- New Diagnostic System Achieves PCR Testing Accuracy
- DNA Biosensor Enables Early Diagnosis of Cervical Cancer
- Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
- Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
- First of Its Kind Technology Detects Glucose in Human Saliva
- Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop
- Novel Noninvasive Test Detects Malaria Infection without Blood Sample
- Portable Optofluidic Sensing Devices Could Simultaneously Perform Variety of Medical Tests
- Point-of-Care Software Solution Helps Manage Disparate POCT Scenarios across Patient Testing Locations
- Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents
- Breakthrough Test Detects Biological Markers Related to Wider Variety of Cancers
- Rapid POC Sensing Kit to Determine Gut Health from Blood Serum and Stool Samples
- Device Converts Smartphone into Fluorescence Microscope for Just USD 50
- Wi-Fi Enabled Handheld Tube Reader Designed for Easy Portability
Channels
Clinical Chemistry
view channel
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read more
Molecular Diagnostics
view channel
Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients
Stroke is the primary cause of disability globally and ranks as the second leading cause of death. However, timely early intervention can prevent severe outcomes. Most strokes are ischemic, resulting from... Read more
Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
Two studies have identified proteins in the blood that could potentially alert individuals to the presence of cancer more than seven years before the disease is clinically diagnosed. Researchers found... Read more (1)_1.jpg "Image: Ultrasound image of micro-histotripsy liberation of biomarkers in a tumor (Photo courtesy of Joy Wang and Pradyumna Kedarisetti)"){kind=small}
_1.jpg "Image: The innovative method to customize and strengthen DNA origami structure promises breakthroughs in medicine (Photo courtesy of Shutterstock)")
Hematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
AI Predicts Tumor-Killing Cells with High Accuracy
Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more
Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read moreMicrobiology
view channel
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. It primarily results from the inappropriate and excessive use of antibiotics, which reduces... Read morePathology
view channel
New AI Tool Classifies Brain Tumors More Quickly and Accurately
Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more
AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
Rapid and accurate intraoperative diagnosis is essential for tumor surgery as it guides surgical decisions with precision. Traditional intraoperative assessments, such as frozen sections based on H&E... Read more
HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
Annually, over 604,000 women across the world are diagnosed with cervical cancer, and about 342,000 die from this disease, which is preventable and primarily caused by the Human Papillomavirus (HPV).... Read more
Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
Breast cancer remains a major cause of cancer-related mortality among women. Breast-conserving surgery (BCS), also known as lumpectomy, is the removal of the cancerous lump and a small margin of surrounding tissue.... Read moreIndustry
view channel
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
